Status:
COMPLETED
Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
Guerbet
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Brief Summary
In this prospective study, the investigators will evaluate and compare the usefulness of functional and volumetric informations obtained by 18F-FDG PET and MRI before and after the palliative chemothe...
Detailed Description
Study cohort will undergo PET/CT and MRI scans prior to chemotherapy and after the first chemotherapy cycle. MRI scans include DCE-MRI and DWI. The following parameters will be calculated using these ...
Eligibility Criteria
Inclusion
- Histologically proven NSCLC
- Newly diagnosed Stage stage IV
- Participant is being considered for the chemotherapy with EGFR TKI as a first line therapy
- At least one measurable primary or other intrathoracic lesion \>= 2cm, according to RECIST
- Performance status of 0 to 2 on the ECOG scale
- Age 18 years or older
- Able to tolerable PET/CT and MRI imaging required by protocol
- Able to give study-specific informed consent
Exclusion
- Pure bronchioloalveolar cell carcinoma histology
- Thoracic radiotherapy, lung surgery or chemotherapy within three months prior to inclusion in the study
- Poorly controlled diabetes
- Prior malignancy
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01482182
Start Date
November 1 2011
End Date
January 1 2014
Last Update
November 20 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea